Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Long-Term Debt Repayments (2022)

Orchestra BioMed Holdings (OBIO) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $5.4 million as the latest value for Q2 2022.

  • Quarterly Long-Term Debt Repayments changed N/A to $5.4 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2022, changed N/A year-over-year, with the annual reading at $10.8 million for FY2023, 68.31% up from the prior year.
  • Long-Term Debt Repayments for Q2 2022 was $5.4 million at Orchestra BioMed Holdings, up from $1.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $5.4 million in Q2 2022, with the low at $1.0 million in Q1 2022.